Lilly links oral obesity drug to 15% weight loss, setting bar for Pfizer in blockbuster battle

Eli Lilly has laid down a marker in the race for the oral obesity market, linking its GLP-1 receptor agonist orforglipron to 14.7% weight loss at 36 weeks. The result sets a high efficacy bar—which could rise higher still at later time points—for Pfizer but leaves ample room to improve on tolerability.